Evicenter
P&T meetings

Azetukalner

Focal onset seizures

Also known as XEN1101
Regulatory submission
NDA submitted September 2026
Launch
Not announced
163 sources

Section 6 of 6

References

163 sources

  1. Al-aqeel et al. (2020) (opens in a new tab)
  2. Ángel Calleja et al. (2022) (opens in a new tab)
  3. Auvin et al. (2023) (opens in a new tab)
  4. Babar et al. (2021) (opens in a new tab)
  5. Becker et al. (2025) (opens in a new tab)
  6. Begley and Durgin (2015) (opens in a new tab)
  7. Ben-Menachem et al. (2016) (opens in a new tab)
  8. Beniczky et al. (2025) (opens in a new tab)
  9. Birbeck et al. (2002) (opens in a new tab)
  10. Blair (2012) (opens in a new tab)
  11. Boccaletti et al. (2024) (opens in a new tab)
  12. Boleti et al. (2024) (opens in a new tab)
  13. Bonnett et al. (2012) (opens in a new tab)
  14. Borghs et al. (2020) (opens in a new tab)
  15. Bradley et al. (2016) (opens in a new tab)
  16. Brandt et al. (2023) (opens in a new tab)
  17. Bresnahan et al. (2019a) (opens in a new tab)
  18. Bresnahan et al. (2019b) (opens in a new tab)
  19. Bresnahan et al. (2020) (opens in a new tab)
  20. Bresnahan et al. (2022) (opens in a new tab)
  21. Bresnahan et al. (2023) (opens in a new tab)
  22. Brigo and Lattanzi (2024) (opens in a new tab)
  23. Brigo et al. (2020) (opens in a new tab)
  24. Brodie et al. (2012) (opens in a new tab)
  25. Brook et al. (2018) (opens in a new tab)
  26. CADTH (2023) (opens in a new tab)
  27. CDC (2024) (opens in a new tab)
  28. Cereghino et al. (2000) (opens in a new tab)
  29. Cervenka et al. (2021) (opens in a new tab)
  30. Chang et al. (2021) (opens in a new tab)
  31. Chen et al. (2018) (opens in a new tab)
  32. Chen et al. (2024) (opens in a new tab)
  33. Chung et al. (2010a) (opens in a new tab)
  34. Chung et al. (2010b) (opens in a new tab)
  35. Chung et al. (2020) (opens in a new tab)
  36. ClinicalTrials.gov NCT03340220 (opens in a new tab)
  37. ClinicalTrials.gov NCT03468725 (opens in a new tab)
  38. ClinicalTrials.gov NCT03796962 (opens in a new tab)
  39. ClinicalTrials.gov NCT04952467 (opens in a new tab)
  40. ClinicalTrials.gov NCT05614063 (opens in a new tab)
  41. ClinicalTrials.gov NCT05716100 (opens in a new tab)
  42. ClinicalTrials.gov NCT05718817 (opens in a new tab)
  43. Czapińska-Ciepiela et al. (2024) (opens in a new tab)
  44. EMA (2018) (opens in a new tab)
  45. Engel et al. (2003) (opens in a new tab)
  46. Engel et al. (2012) (opens in a new tab)
  47. Faught et al. (2008) (opens in a new tab)
  48. FDA (2013) (opens in a new tab)
  49. FDA (2018) (opens in a new tab)
  50. Fiest et al. (2013) (opens in a new tab)
  51. Fiest et al. (2017) (opens in a new tab)
  52. Fisher et al. (2010) (opens in a new tab)
  53. Fisher et al. (2014) (opens in a new tab)
  54. Fisher et al. (2017) (opens in a new tab)
  55. French et al. (2012) (opens in a new tab)
  56. French et al. (2013) (opens in a new tab)
  57. French et al. (2021) (opens in a new tab)
  58. French et al. (2023) (opens in a new tab)
  59. French et al. (2024) (opens in a new tab)
  60. French et al. (2025a) (opens in a new tab)
  61. French et al. (2025b) (opens in a new tab)
  62. GBD 2016 Epilepsy Collaborators (2019) (opens in a new tab)
  63. Glauser et al. (2013) (opens in a new tab)
  64. Greene and Hoshi (2017) (opens in a new tab)
  65. Gupta et al. (2017) (opens in a new tab)
  66. Halloush et al. (2025) (opens in a new tab)
  67. Handforth et al. (1998) (opens in a new tab)
  68. Harden et al. (2017) (opens in a new tab)
  69. Hermann et al. (2021) (opens in a new tab)
  70. Hitiris et al. (2007) (opens in a new tab)
  71. Hu et al. (2025) (opens in a new tab)
  72. Ioannou et al. (2022) (opens in a new tab)
  73. Javarayee et al. (2024) (opens in a new tab)
  74. Jehi et al. (2022) (opens in a new tab)
  75. Johannessen and Landmark (2010) (opens in a new tab)
  76. Josephson et al. (2025) (opens in a new tab)
  77. Joshi et al. (2019) (opens in a new tab)
  78. Kanner et al. (2018a) (opens in a new tab)
  79. Kanner et al. (2018b) (opens in a new tab)
  80. Kanner et al. (2023) (opens in a new tab)
  81. Karnes et al. (2021) (opens in a new tab)
  82. Karoly et al. (2019) (opens in a new tab)
  83. Kenney et al. (2022) (opens in a new tab)
  84. Klein et al. (2015) (opens in a new tab)
  85. Kobau et al. (2023) (opens in a new tab)
  86. Krauss et al. (2012) (opens in a new tab)
  87. Krauss et al. (2020) (opens in a new tab)
  88. Kwan and Brodie (2000) (opens in a new tab)
  89. Kwan and Brodie (2025) (opens in a new tab)
  90. Kwan et al. (2010) (opens in a new tab)
  91. Labate et al. (2025) (opens in a new tab)
  92. Lado et al. (2024) (opens in a new tab)
  93. Laskier et al. (2023) (opens in a new tab)
  94. Lattanzi et al. (2022) (opens in a new tab)
  95. Lattanzi et al. (2024) (opens in a new tab)
  96. Lattanzi et al. (2025) (opens in a new tab)
  97. Lee et al. (2021) (opens in a new tab)
  98. Lévesque et al. (2019) (opens in a new tab)
  99. Li et al. (2025) (opens in a new tab)
  100. Liu et al. (2018) (opens in a new tab)
  101. Löscher et al. (2021) (opens in a new tab)
  102. Marson et al. (2021) (opens in a new tab)
  103. Martins (2026) (opens in a new tab)
  104. Mbizvo et al. (2020) (opens in a new tab)
  105. Medicaid.gov National Average Drug Acquisition Cost (2026) (opens in a new tab)
  106. Mesraoua et al. (2025) (opens in a new tab)
  107. MHRA (2025) (opens in a new tab)
  108. Morrell et al. (2011) (opens in a new tab)
  109. Morris et al. (2013) (opens in a new tab)
  110. Moura et al. (2022) (opens in a new tab)
  111. Nair et al. (2020) (opens in a new tab)
  112. Narducci et al. (2025) (opens in a new tab)
  113. NICE (2021) (opens in a new tab)
  114. NICE (2021) (opens in a new tab)
  115. NICE (2022) (opens in a new tab)
  116. NICE (2022) (opens in a new tab)
  117. NICE (2022) (opens in a new tab)
  118. NICE (2022) (opens in a new tab)
  119. NICE (2022) (opens in a new tab)
  120. Panebianco et al. (2020) (opens in a new tab)
  121. Panebianco et al. (2022) (opens in a new tab)
  122. Paoletti et al. (2025) (opens in a new tab)
  123. Perucca and Taglialatela (2025) (opens in a new tab)
  124. Pharmaceutical Technology (2024) (opens in a new tab)
  125. Phillips et al. (2018) (opens in a new tab)
  126. Porter et al. (2023) (opens in a new tab)
  127. Premoli et al. (2019) (opens in a new tab)
  128. Rajadhyaksha et al. (2025) (opens in a new tab)
  129. Rosendahl et al. (2026) (opens in a new tab)
  130. Rudkowska et al. (2026) (opens in a new tab)
  131. Salanova et al. (2015) (opens in a new tab)
  132. Salanova et al. (2021) (opens in a new tab)
  133. Sarmast et al. (2020) (opens in a new tab)
  134. Scheffer et al. (2017) (opens in a new tab)
  135. Scott et al. (2017) (opens in a new tab)
  136. Semah et al. (1998) (opens in a new tab)
  137. Shah et al. (2013) (opens in a new tab)
  138. Shorvon et al. (2000) (opens in a new tab)
  139. Singh and Carson (2024) (opens in a new tab)
  140. Sperling et al. (2015) (opens in a new tab)
  141. Sperling et al. (2021) (opens in a new tab)
  142. Sultana et al. (2021) (opens in a new tab)
  143. Tatum et al. (2021) (opens in a new tab)
  144. Thurman et al. (2017) (opens in a new tab)
  145. Vismer et al. (2015) (opens in a new tab)
  146. Vonck et al. (2025) (opens in a new tab)
  147. WHO Drug Information Recommended INN List 90 (2023) (opens in a new tab)
  148. Wiebe et al. (2001) (opens in a new tab)
  149. Wu et al. (2019) (opens in a new tab)
  150. Xenon Pharmaceuticals AAN 2026 data release (2026) (opens in a new tab)
  151. Xenon Pharmaceuticals AES 2025 data release (2025) (opens in a new tab)
  152. Xenon Pharmaceuticals EEC 2026 release (2026) (opens in a new tab)
  153. Xenon Pharmaceuticals Form 10-K (2026) (opens in a new tab)
  154. Xenon Pharmaceuticals Form 10-Q (2026) (opens in a new tab)
  155. Xenon Pharmaceuticals J.P. Morgan Healthcare Conference release (2026) (opens in a new tab)
  156. Xenon Pharmaceuticals NDA submission release (2026) (opens in a new tab)
  157. Xenon Pharmaceuticals neurology pipeline update (2023) (opens in a new tab)
  158. Xenon Pharmaceuticals OLE data release (2024) (opens in a new tab)
  159. Xenon Pharmaceuticals Q2 2026 results release (2026) (opens in a new tab)
  160. Xenon Pharmaceuticals X-TOLE topline release (2021) (opens in a new tab)
  161. Xenon Pharmaceuticals X-TOLE2 topline release (2026) (opens in a new tab)
  162. Zack and Kobau (2017) (opens in a new tab)
  163. Zhang et al. (2024) (opens in a new tab)